![]() |
Volumn 115, Issue 1, 2001, Pages 79-83
|
Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease
e
Roche Norge AS
(Norway)
|
Author keywords
Cold agglutinin; Haemolytic anaemia; Lymphoproliferative; Rituximab; Therapy
|
Indexed keywords
ALKYLATING AGENT;
ALPHA INTERFERON;
CD20 ANTIGEN;
CHLORAMBUCIL;
CLADRIBINE;
COLD AGGLUTININ;
CORTICOSTEROID DERIVATIVE;
CYCLOPHOSPHAMIDE;
MONOCLONAL ANTIBODY;
PURINE DERIVATIVE;
RITUXIMAB;
ADULT;
AGED;
ARTICLE;
B CELL LYMPHOMA;
B LYMPHOCYTE;
BONE MARROW BIOPSY;
CLINICAL ARTICLE;
CONTROLLED STUDY;
DRUG EFFECT;
DRUG EFFICACY;
FEMALE;
HEMOGLOBIN DETERMINATION;
HUMAN;
LYMPHOCYTE CLONE;
LYMPHOCYTE PROLIFERATION;
MALE;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
AGED;
AGED, 80 AND OVER;
ANEMIA, HEMOLYTIC, AUTOIMMUNE;
ANTIBODIES, MONOCLONAL;
ANTIGENS, CD20;
B-LYMPHOCYTES;
BONE MARROW CELLS;
CHRONIC DISEASE;
FEMALE;
HEMOGLOBINS;
HUMANS;
IMMUNOGLOBULIN M;
MALE;
MIDDLE AGED;
PROSPECTIVE STUDIES;
TREATMENT OUTCOME;
|
EID: 0034783228
PISSN: 00071048
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1365-2141.2001.03078.x Document Type: Article |
Times cited : (114)
|
References (24)
|